SOBI — Swedish Orphan Biovitrum AB (publ) Share Price
0.000.00%
Last trade - 00:00- SEK90.33bn
- SEK105.93bn
- SEK26.03bn
- 98
- 26
- 60
- 69
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16.31 | ||
| PEG Ratio (f) | 0.75 | ||
| EPS Growth (f) | 27.93% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.24 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 20.61 | ||
| Price to Sales | 3.47 | ||
| EV to EBITDA | 11.33 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.95% | ||
| Return on Equity | 10.48% | ||
| Operating Margin | 21.61% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 15,261 | 15,529 | 18,790 | 22,123 | 26,027 | 28,322.25 | 31,992.68 | 12.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -17.01 | -6.86 | +15.62 | -15.04 | +36.08 | +24.59 | +34.23 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
Directors
- Hakan Bjorklund NEC (65)
- Guido Oelkers PRE (56)
- Henrik Stenqvist CFO (54)
- Anne De Jonge Schuermans CTO (49)
- Armin Reininger CSO (64)
- Torbjorn Hallberg GCN (52)
- Paula Treutiger DIR (54)
- Duane Barnes OTH (61)
- Sofiane Fahmy OTH (49)
- Mahmood Ladha OTH (57)
- Norbert Oppitz OTH (54)
- Daniel Rankin OTH (41)
- Ravi Rao OTH (53)
- Pia Axelson DRC (59)
- Erika Husing DRC (48)
- Lennart Johansson DRC (66)
- Helena Saxon DRC (51)
- Annette Clancy IND (67)
- Matthew Gantz IND (56)
- Staffan Schueberg IND (52)
- Elisabeth Svanberg IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 20th, 1939
- Public Since
- September 15th, 2006
- No. of Shareholders
- 24,398
- No. of Employees
- 1,840
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 343,442,827
- Address
- Norra Stationsgatan 93A, STOCKHOLM, 112 76
- Web
- https://www.sobi.com/
- Phone
- +46 86972000
- Auditors
- Ernst & Young AB
Upcoming Events for SOBI
Q1 2025 Swedish Orphan Biovitrum AB (publ) Earnings Call
Swedish Orphan Biovitrum AB (publ) Annual Shareholders Meeting
Swedish Orphan Biovitrum AB (publ) Annual Shareholders Meeting
Q2 2025 Swedish Orphan Biovitrum AB (publ) Earnings Release
Similar to SOBI
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cinclus Pharma Holding publ AB
OMX Nordic Exchange Stockholm
Corline Biomedical AB
OMX Nordic Exchange Stockholm
FAQ
What is the Swedish Orphan Biovitrum AB (publ) share price?
As of Today at 23:30 UTC, shares in Swedish Orphan Biovitrum AB (publ) are trading at SEK263.00. This share price information is delayed by 15 minutes.
How has the Swedish Orphan Biovitrum AB (publ) share price performed this year?
Shares in Swedish Orphan Biovitrum AB (publ) last closed at SEK263.00 and the price had moved by +2.81% over the past 365 days. In terms of relative price strength the Swedish Orphan Biovitrum AB (publ) share price has outperformed the FTSE Global All Cap Index by +1% over the past year.
What are the analyst and broker recommendations for Swedish Orphan Biovitrum AB (publ)?
The overall consensus recommendation for Swedish Orphan Biovitrum AB (publ) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Swedish Orphan Biovitrum AB (publ) dividend yield?
Swedish Orphan Biovitrum AB (publ) does not currently pay a dividend.
Does Swedish Orphan Biovitrum AB (publ) pay a dividend?
Swedish Orphan Biovitrum AB (publ) does not currently pay a dividend.
When does Swedish Orphan Biovitrum AB (publ) next pay dividends?
Swedish Orphan Biovitrum AB (publ) does not currently pay a dividend.
How do I buy Swedish Orphan Biovitrum AB (publ) shares?
To buy shares in Swedish Orphan Biovitrum AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Swedish Orphan Biovitrum AB (publ)?
As of the previous close price of SEK263.00, shares in Swedish Orphan Biovitrum AB (publ) had a market capitalisation of SEK90.33bn.
Where are Swedish Orphan Biovitrum AB (publ) shares listed?
Here are the trading details for Swedish Orphan Biovitrum AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: SOBI
What kind of share is Swedish Orphan Biovitrum AB (publ)?
Based on an overall assessment of its quality, value and momentum Swedish Orphan Biovitrum AB (publ) is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Swedish Orphan Biovitrum AB (publ) share price forecast for 2025?
The analyst consensus target price for shares in Swedish Orphan Biovitrum AB (publ) is SEK370.46. That is 40.86% above the last closing price of SEK263.00.
Analysts covering Swedish Orphan Biovitrum AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of SEK14.63 for the next financial year.
Find out moreWhat is the trend in the Swedish Orphan Biovitrum AB (publ) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Swedish Orphan Biovitrum AB (publ). Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -15.38%.
As of the last closing price of SEK263.00, shares in Swedish Orphan Biovitrum AB (publ) were trading -14.01% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Swedish Orphan Biovitrum AB (publ) PE Ratio?
The Swedish Orphan Biovitrum AB (publ) PE ratio based on its reported earnings over the past 12 months is 16.31. The shares last closed at SEK263.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Swedish Orphan Biovitrum AB (publ)?
Swedish Orphan Biovitrum AB (publ)'s management team is headed by:
- Hakan Bjorklund - NEC
- Guido Oelkers - PRE
- Henrik Stenqvist - CFO
- Anne De Jonge Schuermans - CTO
- Armin Reininger - CSO
- Torbjorn Hallberg - GCN
- Paula Treutiger - DIR
- Duane Barnes - OTH
- Sofiane Fahmy - OTH
- Mahmood Ladha - OTH
- Norbert Oppitz - OTH
- Daniel Rankin - OTH
- Ravi Rao - OTH
- Pia Axelson - DRC
- Erika Husing - DRC
- Lennart Johansson - DRC
- Helena Saxon - DRC
- Annette Clancy - IND
- Matthew Gantz - IND
- Staffan Schueberg - IND
- Elisabeth Svanberg - IND